Frontiers in Pediatrics · 2019 · 33 citations · 32 references
MedicineHematologyPediatricsPediatric HematologyPediatric RheumatologyRheumatologyAutoimmune DiseasesAutoimmune Hematologic DiseasePediatric Clinical ImmunologyPediatric Rheumatologic Laboratory EvaluationHematological AnalysisHematological PhenotypingImmune-mediated CytopeniasLaboratory Results ReportingMembranoproliferative Glomerulonephritis RecurrencePediatric GlomerulonephritisPediatric Immune DysregulationPrimary Immunodeficiency Disorders
Evans syndrome (ES) is a rare but challenging condition, characterized by recurrent and refractory cytopenia episodes. Recent discoveries highlighted that an appropriate diagnostic workup is fundamental to identify an underlying immune dysregulation such as primary immunodeficiencies or a rheumatological disease. We hereby describe clinical features and laboratory results of 12 pediatric patients affected by ES referred to the Pediatric Onco-Hematology Unit of Bologna. Patients experienced a median of four acute episodes of cytopenia with 9 years as median age at the onset of symptoms. In 8/12 (67%) patients an underlying etiology, primary immunodeficiencies, or rheumatological disease was identified. In 4/12 children, other immune manifestations were associated (Thyroiditis, Celiac disease, Psoriasis, Vitiligo, Myositis, Membranoproliferative Glomerulonephritis). ES remained the primary diagnosis in four patients (33%). At a median follow-up time of 4 years, 5/12 (42%) patients revealed a chronic ITP, partially responsive to second line therapy. Immunoglobulin Replacement Therapy (IRT) was effective with a good hematological values control in three patients with a secondary ES (ALPS, CVID, and a patient with Rubinstein Taybi Syndrome and a progressive severe B cell deficiency with hypogammaglobulinemia). Our experience highlights that, in pediatric patients, ES is often only the first manifestation of an immunological or rheumatological disease, especially when cytopenias are persistent or resistant to therapy, with an early-onset or when are associated with lymphadenopathy.
32
Michelle Petri, Ana‐Maria Orbai, Graciela S. Alarcón et al. · Arthritis & Rheumatism · 2012 · 5.3K citations · Full text
Life Sciences, Immunology, Clinical Classification Systems +11
Francesco Rodeghiero, Roberto Stasi, Terry Gernsheimer et al. · Blood · 2008 · 2.7K citations · Full text
Medicine, Hematology, Immunology +15
Immune dysregulation in human subjects with heterozygous germline mutations in <i>CTLA4</i>
Hye Sun Kuehn, Weiming Ouyang, Bernice Lo et al. · Science · 2014 · 846 citations
Life Sciences, Genetics, Immunology +17
Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations
Desirée Schubert, Claudia Bode, Rupert Kenefeck et al. · Nature Medicine · 2014 · 822 citations · Full text
Life Sciences, Genetics, Immunology +14